Absolute neutrophil count (ANC) >= 1000/mm^3, independent of growth factor support, documented within 14 days of registration
Absolute neutrophil count (ANC) > 1,000 cells/dL (1.0 x 10e9/L) (growth factor cannot be used within the previous 7 days)
Absolute neutrophil count ?1,000/mm3 without growth factor use ? 7 days prior to treatment (cycle 1 day 1, C1D1)
Absolute neutrophil count (ANC): >= 750/mm^3, must be at least 7days after last dose of growth factor
Absolute neutrophil count < 1000 cells/mm^3. No growth factors allowed within 1 week of enrollment
Absolute neutrophil count (ANC) ? 1,000 cells/mm3 (1.0 x 109/L) (Growth factors cannot be used within 10 days (14 days for pegfilgrastim) prior to initiation of therapy)
Absolute neutrophil count > 1000/mm^3 without the support of growth factors
Absolute neutrophil count (ANC) >= 1,000 cell/mm^3 without growth factor support, obtained =< 14 days prior to registration
STRATUM A: Absolute neutrophil count (ANC) >= 1000/mm^3 without growth factor support within 7 days of the test
STRATUM B: ANC >= to 1000/mm^3 without growth factor support within 7 days of the test
STRATUM C: ANC >= 1,000/mm^3 without growth factor support within 7 days of the test
Absolute neutrophil count (ANC) >= 1000/mm^3 independent of growth factor support
To be performed within 14 days prior to day 1 of protocol therapy: Absolute neutrophil count (ANC) >= 1,500/mm^3\r\n* NOTE: growth factor support is not permitted to normalize baseline ANC parameters, however subsequent growth factor administration is permitted as standard supportive care
Absolute neutrophil count (ANC) > 1,000/mm^3 independent of growth factor support
Absolute neutrophil count (ANC) >= 1,000 cells/mm^3 without growth factors within 1 week of the initiation of treatment
Absolute neutrophil count (ANC) < 1,000/mm3 without growth factor support within 7 days prior to testing
Participants with an absolute neutrophil count (ANC) >= 1000/mm^3, within 21 days of initiation of protocol therapy; growth factor within 7 days of screening is not allowed to meet ANC eligibility criteria
Participants with an absolute neutrophil count (ANC) < 1000/mm^3, within 21 days of initiation of protocol therapy; growth factor within 7 days of screening is not allowed to meet ANC eligibility criteria
Absolute neutrophil count (ANC) >= 1,000/mm^3 without transfusion or growth factor support for at least 1 week
Obtained =< 14 days prior to registration: Absolute neutrophil count (ANC) >= 1,000 cell/mm^3 without growth factor support
Within 14 days prior to planned start of treatment: Absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Growth factor is not permitted within 14 days of ANC assessment unless cytopenia is secondary to disease involvement
Absolute neutrophil count (ANC) >= 1000/mm^3 independent of growth factor support
Absolute neutrophil count (ANC) ? 1.5 K/mm^3 (must be stable off any growth factor within 4 weeks of first study drug administration)
PART 2 GROUP 1 INCLUSION CRITERIA: Peripheral absolute neutrophil count (ANC) >= 1000/mm^3 (1.0 x 10^9/L) without granulocyte growth factor for >= 7 days
PART 2 GROUP 2A INCLUSION CRITERIA: Peripheral ANC >= 1000/mm^3 (1.0 x 10^9/L) without granulocyte growth factor for >= 7 days
PART 2 GROUP 3 INCLUSION CRITERIA: Peripheral ANC >= 1000/mm^3 (1.0 x 10^9/L) without granulocyte growth factor for >= 7 days
Absolute neutrophil count >= 1000 cells/mm^3, with or without transfusion support; NOTE: If the patient’s bone marrow biopsy shows greater than or equal to 50% plasma cells, absolute neutrophil count (ANC) > 500 cells/mm^3 (transfusion support or growth factor support is acceptable)
Absolute neutrophil count >= 1,000/mm^3 without growth factor use =< 7 days prior to C1D1
Absolute neutrophil count (ANC) >= 1,000 cells/mm^3 without growth factors within 1 week of the initiation of treatment
Absolute neutrophil count (ANC) >= 1000/mm^3; growth factor is not permitted within 14 days of neutrophil assessment
Absolute neutrophil count (ANC) >= 1000/mm^3 or >= 750/mm^3 in the setting of marrow involvement by disease (independent of growth factor or transfusion support)
An absolute neutrophil count (ANC) > 1,000/mm^3 (patients who have bone marrow infiltration by MCL are eligible if their ANC is >= 500/mm^3 [growth factor allowed]; these patients should be discussed with either the principal investigator [PI] or Co-PI of the study for final approval)
Absolute neutrophil count (ANC) ? 1000/mm3, independent of growth factor support;
Absolute neutrophil count (ANC) 550/cu mm (off myeloid growth factors)
Absolute neutrophil count (ANC) >= 1,000/mm^3 without growth factor support
Relapsed/refractory MCL: Absolute neutrophil count (ANC) >= 500/mm^3; (patients who have bone marrow infiltration by MCL are eligible if their ANC is >= 500/mm^3 [growth factor allowed]; these patients should be discussed with either the principal investigator [PI] or Co-PI of the study for final approval)
Absolute neutrophil count (ANC) >= 1.0 x 10^9/L; screening ANC should be independent of growth factor support for over one week for all patients
Within 14 days prior to day 1 of protocol therapy unless otherwise stated: Absolute neutrophil count (ANC) >= 1,000/mm^3\r\n* NOTE: Growth factor is not permitted within 14 days of ANC assessment unless cytopenia is secondary to disease involvement
Absolute neutrophil count (ANC) >= 1,500/mm^3 (without transfusion or growth factor support)
To be performed within 28 days prior to day 1 of protocol therapy: Absolute neutrophil count (ANC) >= 1500/mm^3\r\n* NOTE: Growth factor is not permitted within 14 days of ANC assessment unless cytopenia is secondary to disease involvement
Absolute neutrophil count (ANC) >= 1,000 cell/mm^3 without growth factor support within 14 days prior to registration
Participants with an absolute neutrophil count (ANC) < 1000/mm^3, within 21 days of initiation of protocol therapy; growth factor within 7 days of screening is not allowed to meet ANC eligibility criteria
Absolute neutrophil count (ANC) < 1,000 cells/mm^3 within 21 days of initiation of protocol therapy; growth factor administration is not allowed to meet ANC eligibility criteria
ANC ?1000/mm3 (?1.0 × 109/L) without growth factor support for 14 days
Within 14 days prior to registration: Absolute neutrophil count (ANC) >= 1,000 cells/mm^3 without growth factor support
Within 72 h of initiating study treatment: Absolute neutrophil count (ANC) >= 1000/mm^3; Note: transfusions of blood and blood products as well as growth factor support are prohibited within 14 days prior to the first dose of study treatment
Within 28 days prior to signing informed consent: Absolute neutrophil count (ANC) >= 1,000/mm^3, independent of growth factor support
Subjects with an absolute neutrophil count (ANC) < 1000 cells/mm3; growth factors may not be used to meet ANC eligibility criteria
Absolute neutrophil count (ANC) ? 1000/mm3 (screening ANC should be independent of growth factor support for ? 1 week)
Participants with an absolute neutrophil count (ANC) < 1000 cells/mm^3 at time of screening evaluation; growth factor may not be used to meet ANC eligibility criteria within 14 days of obtaining screening evaluation
Absolute neutrophil count (ANC) > 1000/mm^3 without growth factors or transfusions
Absolute neutrophil count (ANC) > 1,500/mm^3; (patients who have bone marrow infiltration by MCL are eligible if their ANC is >= 1000/mm^3 [growth factor not allowed] or their platelet level is >= 50,000/mm^3)
Participants with an absolute neutrophil count (ANC) < 1500 cells/mm^3 at time of screening evaluation; growth factor may not be used to meet ANC eligibility criteria within 7 days of obtaining screening evaluation
Absolute neutrophil count (ANC) > 1,500 (growth factors permitted)
Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (>= 1500/mm^3) may be supported by transfusion and/or hematopoetic growth factors
Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (growth factors not permitted to make eligible)
Absolute neutrophil count (ANC) >= 1,000 cells/mm^3 (without platelet transfusion or myeloid growth factor support within two weeks of screening)
Absolute neutrophil count (ANC) > 1,000/mm^3; (patients who have bone marrow infiltration by MCL are eligible if their ANC is 500/mm^3 [growth factor allowed] or their platelet level is equal to or > than 30,000/mm^3)
Absolute neutrophil count (ANC) >= 1500 cells/mm3 without growth factor support
Absolute neutrophil count ? 1,500/mm3 (not supported by growth factors in the preceding 21 days);
Peripheral absolute neutrophil count (ANC) >= 1000/mm^3; \r\n* Note: must be > 7 days from use of hematopoietic growth factor or 21 days from pegfilgastrim
Absolute neutrophil count (ANC) < 1,000/mm3 without growth factor support within 7 days prior to testing
Absolute neutrophil count (ANC) ? 1,500/µL (without growth factors)
Absolute neutrophil count >=1,500 per cubic millimeter (/mm^3), not supported by growth factor
Absolute neutrophil count (ANC) >= 1500/mm^3 (1.5 x 10^9/L) (participants receiving transfusion, erythropoietin, or myeloid growth factor support will be eligible for this study)
Absolute neutrophil count (ANC) ? 1000/mm³ within 21 days prior to randomization. Screening ANC should be independent of growth factor support for ? 1 week.
Absolute neutrophil count (ANC) >= 1,000 cells/dL (1.0 x 10^9/L) (growth factors cannot be used within 7 days of first drug administration)
Absolute neutrophil count >1000 cells/mm^3 without growth factors for 7 days.
Absolute neutrophil count >= 500 cells/mm^3 (0.5 x 10^9/L); growth factor allowed to achieve
Absolute neutrophil count (ANC) > 1000/mm^3 without growth factors or transfusions
